Protalix BioTherapeutics (PLX) Issues 2025 Letter to Stockholders

Go back to Protalix BioTherapeutics (PLX) Issues 2025 Letter to Stockholders

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

December 23, 2024 6:50 AM EST

CARMIEL, Israel, Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its... More